

11 March 2008

The Manager - Companies
Australian Stock Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

(1 page by email)

Dear Madam,

**PRESENTATION OF BIOTRON'S HIV AND HCV PROGRAMS AT
INTERNATIONAL PARTNERING MEETING**

The Directors are pleased to advise that Biotron Limited ('Biotron') has presented details of its HIV and Hepatitis C virus (HCV) clinical programs at an international partnering conference this week.

The 5th Anti-Infectives Partnering & Deal Making Summit, held in Philadelphia, PA, USA, is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as to explore potential collaborations and to learn about relevant anti-infective issues and deals that affect the industry.

Biotron's abstract was the only one selected to be presented as an oral presentation at this conference, which included audience of experts from leading organisations such as AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Global Alliance for TB Drug Development, GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth, and many more.

Biotron's Managing Director, Dr Michelle Miller, presented an overview of the Company's HIV and HCV programs, as well as a summary of data from the Phase I clinical trial and outlined the clinical program set out for the rest of 2008.

As previously announced, the Phase I trial was successful, indicating that BIT225 was well tolerated, with no dose limiting toxicities. Preliminary analysis indicated that potentially therapeutic blood levels of BIT225 were achieved, based on calculations extrapolated from preclinical *in vitro* antiviral efficacy studies.

BIT225 is a new first-in class drug in development for treatment of both HIV and HCV infections. It offers the potential to significantly advance treatments of both these debilitating infections. The market for both these diseases is very large, with the worldwide market for HCV currently almost US\$3.0 billion. The US market alone for HIV is over US\$3.3 billion.

The acceptance of an abstract for oral presentation by Biotron at this international partnering meeting demonstrates the high level of international interest in the Company's programs. Biotron is currently progressing documentation for two new human trials of BIT225 through regulatory and ethics approval processes. Upon approval, Biotron will commence Phase Ib/IIa clinical trials in both HIV and HCV infected subjects. It is expected that these trials will commence in the second quarter of 2008 and will run over approximately 6 months.

For further information, please contact Dr. Michelle Miller, CEO, on (61-2) 92478212.

Yours sincerely

A handwritten signature in black ink, appearing to read 'PJN', with a stylized flourish at the end.

Peter J. Nightingale
Company Secretary

pjn4301